Takeda Oncology
Maggie Baker currently serves as Associate Director of Global Program Management at Takeda Oncology, where responsibilities include competitive intelligence leadership for the GI disease area strategy team and providing insights to support various stages of R&D programs. Prior to this role, Maggie was a Senior Manager and Consultant at IQVIA, successfully executing numerous engagements in areas such as market access strategy and product valuations. Experience also includes academic positions at Boston University School of Medicine, where research focused on dendritic cell dysfunction in systemic lupus erythematosus, alongside teaching roles. Early career work involved research at Northwestern University's Feinberg School of Medicine and The Field Museum. Maggie holds a PhD in Molecular and Translational Medicine from Boston University and a BS in Biological Sciences from the University of Notre Dame.
This person is not in any teams
This person is not in any offices
Takeda Oncology
20 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.